Detection of Trichomonas vaginalis (TV) in Female Urine and Vaginal Specimens Using a Transcription-Mediated Amplification (TMA) Assay Martin DH1, Lillis.

Slides:



Advertisements
Similar presentations
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Advertisements

RESULTS: After Discordant Analysis RESULTS: Discordant Testing
Insert the central bristles into the endocervical canal deep enough to allow the shorter bristles to fully contact the ectocervix. Push gently, and rotate.
Analytical Sensitivity of the Urine-Based APTIMA® Trichomonas vaginalis molecular assay using the automated Tigris® Platform A.H. Freeman1, M.W. Pandori2,
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Evaluation of the.
STABILITY OF SEEDED SWAB SPECIMENS FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS IN THE GEN-PROBE APTIMA TEST J Schachter and J Moncada. University of California,
Number of specimens tested
Clearance of Chlamydial Ribosomal RNA by APTIMA Combo 2® Testing in Women With Chlamydia Treated with Azithromycin C.A. Renault, 1 D.M. Israelski, 1 V.
PREVALENCE OF CHLAMYDIA TRACHOMATIS, NEISSERIA GONORRHOEAE AND TRICHOMONAS VAGINALIS IN YOUNG WOMEN IN KENYA USING THE GEN-PROBE APTIMA ASSAYS J Moncada.
Figure 1. Trichomonas Assay Procedure
Analytical Performance of the APTIMA HPV Assay on the PANTHER Analyzer
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Abstract There.
Clinical Performance of the APTIMA HPV Assay for Detection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens C. Hill1, J. Dockter1,
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Sexually Transmitted Disease (STD) Surveillance Report, 2010
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
By Gracie Canales August 10, 2010
Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Transmission of Chlamydia trachomatis between heterosexual sex partners PRELIMINARY RESULTS FROM A GENOTYPE-SPECIFIC CONCORDANCE STUDY.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
PACE 2C Genetic probe screening for C. Trachomatis & N. Gonorrhoeae in Endocervical and Male urethral specimens Heidi Philips and Michael S. Joseph.
Self-Collected Vaginal Specimens for the Detection of Multiple STIs in Adolescent Detainees Cynthia M. Holland, M.D., M.P.H., Harold C. Wiesenfeld, M.D.,
NEW Product MAY 2006 STREPTO B ID NEW chromogenic media available ! STREPTO B ID NEW PRODUCT in the bMx offer SECOND in the NEW PREVENTION range dedicated.
Molecular Testing and Clinical Diagnosis Amplified nucleic acid testing Part III.
Detection of Chlamydia trachomatis (CT) & Neisseria gonorrhoeae(GC) by APTIMA COMBO 2 ASSAY Molecular Diagnostics Instructor: Dr. Nancy McQueen Date June.
Region I Advisory Board Meeting Wells Beach, ME June 9, 2008 Use and Verification of STD Nucleic Acid Amplification Tests for non-FDA Cleared Clinical.
OnSite Gonorrhea Rapid Test (Strip)
Distribution of Trichomonas vaginalis Among Women at High Risk for HIV Infection Barbara Van Der Pol, James Williams, Jacquelyn Murphy and the Project.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;
COBAS AmpliPrep/Cobas TaqMan HIV-1 Test
Multiple Choice Questions for discussion
explain how crime scene evidence is
Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students R.L. Winer, Shu-Kuang Lee, J.P. Hughes, D.
TEAM CASE STUDY 3. EUKARYOTIC – PROTOZOA.
Unit 5: Specialised Techniques: STI Prevalence Assessment and Combined STI/HIV Behavioural Surveillance Surveys #4-5-1.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
Region I Laboratory Update CDC National Infertility Prevention Project Boston, Massachusetts November 15, 2010 Richard Steece, Ph.D., D(ABMM) Laboratory.
Strand Displacement Amplification Presented by Lisa Smith & Apollo Kacsinta.
The Impact of Introducing “Express Visits” for Asymptomatic Persons Seeking STD Services in a Busy Urban STD Clinic System, Borrelli J 1, Paneth-Pollak.
Julia Robbins August 11, Objectives Clinical Significance of MRSA in Healthcare Setting Principle of assay Assay Procedure Assay Perfomance.
SSuN Cycle 2 SSuN Part B Laboratory Component: Trichomonas Resistance Evaluation Bob Kirkcaldy, Lori Newman, Kristen Mahle December 4, 2008.
HCV PCR By Henrietta Orji July 31 st, 2010 Hepatitis C Virus by Polymerase Chain Reaction.
Molecular Testing and Clinical Diagnosis
Reproductive block Objectives Name various etiological agents causing sexually transmitted diseases (STD) Describe the clinical presentations.
Bob Kirkcaldy, Nicholas Gaffga, Lori Newman
Sexually Transmitted Disease (STD) Surveillance Report, 2008 Minnesota Department of Health STD Surveillance System Minnesota Department of Health STD.
CONCLUSIONS Amended Abstract Detection of GBS Directly from ESwab Collected Samples Using the BD MAX™ GBS Assay Suzane Silbert, Talita T. Rocchetti, Alicia.
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
The Dublin Well Woman Centre and The National Virus Reference Laboratory  Approved by ICGP Ethics Committee.
Evaluation of 5 different tests for Trichomonas vaginalis infection and cost effective planning for clinical implementation B. Nathan 1, J Appiah 2, D.
Gabriella Bathgate, Melissa Perry, John White
What’s New in STI Testing?
Seeking HIV-testing Only: Missed Opportunity for HIV Prevention?
Extra-genital samples for gonorrhoea and chlamydia in women and MSM Self-taken samples analysed separately compared with self-taken pooled samples Janet.
Vaginal Swabs Clinical Information Why? Murray Robinson
Xth International Conference on AIDS and STD in Africa, December 1997
II The flagellates A flagellate: is a cell or organism with one or more whip-like organelles from ectoplasm called flagella . The flagellate protozoa includes:
Modern diagnosis of Trichomonas vaginalis infection
School of Life and Health Sciences, University of Ulster Jordanstown
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
ASM 2017 Microbe Annual Meeting Sunday-507
A study of high risk African American women, 15 to 21 years of age
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
II The flagellates A flagellate: is a cell or organism with one or more whip-like organelles from ectoplasm called flagella . The flagellate protozoa includes:
ImmunoWELL Zika Virus Serology.
Can Self-collected Vaginal Swabs Facilitate Testing for Repeat Chlamydia trachomatis Infections among STD Clinic Clients Good morning everyone! I am going.
explain how crime scene evidence is
Nucleic Acid Amplification Tests for the Diagnosis of Chlamydia trachomatis Rectal Infections Bachmann LH1,2, Johnson R3, Cheng H1, Markowitz L3, Papp.
Presentation transcript:

Detection of Trichomonas vaginalis (TV) in Female Urine and Vaginal Specimens Using a Transcription-Mediated Amplification (TMA) Assay Martin DH1, Lillis RA1, Nsuami M1, Smith B1, Cammarata C1, Diodene D1, and Dicky K2 1LSU Health Sciences Center and the Gulf South STI TM Cooperative Research Center, New Orleans, LA 2Gen-Probe Incorporated, San Diego, CA U.S.A. ABSTRACT Objectives: To determine the sensitivity and specificity of a new, research-use TMA assay for the detection of TV in female urine and vaginal swab (VS) specimens. Methods: Women greater than 17 years old attending the New Orleans STD clinic were enrolled. A first voided urine specimen was obtained initially. At the time of the vaginal speculum examination, swab specimens were obtained for InPouch TV culture (BioMed Diagnostics, Inc., CA) and the TMA assay. The TMA assay includes a magnetic bead-based target capture step, TMA, and a Hybridization Protection Assay (HPA) for detection following the standard APTIMA (Gen-Probe Incorporated) assay protocols. Culture was used to determine the infection status of each subject. Results: Four hundred women were enrolled, of whom 95% were African American. TV cultures of vaginal swabs were positive in 87 (21.8%) of the subjects. The sensitivity of the TMA assay in urine and VS specimens was 93.6% and 100%, respectively, while the specificity was 97.4% and 48.9%, respectively. As there appeared to be a contamination problem with VS specimens for the TMA assay, all clinical and laboratory procedures were reviewed. This investigation revealed that a common container used to temporarily hold vaginal swabs while the investigator completed the pelvic examination was the likely source even though it appeared that only the shafts of the swabs directly touched the container walls. Conclusions: The data from this study suggests that TMA testing of female urine specimens could be a useful, non-invasive TV screening assay. A urine specimen placed in the TMA assay processing medium for the purpose of C. trachomatis and N. gonorrhoeae testing also could be tested for TV, thus efficiently adding this organism to the TMA STD screening repertoire. Additionally, clinicians should be aware of the potential for contaminating specimens intended for nucleic acid amplification testing. The Tvag TMA assay procedure, including target capture, TMA and HPA steps is illustrated in Figure 1. The following is a summary of each step: Target rRNA is separated from the other specimen components and the transport media by the addition of Target Capture Reagent, magnetic bead separation, and washing using a target capture system (Figure 2). Amplification Reagent, Oil and Enzyme Reagent are added to the rRNA target on the magnetic beads. Isothermal TMA amplification occurs at 42oC (Figure 3). Detection occurs by HPA (Figure 4) and the reaction is read as Relative Light Units (RLU) in a LEADER® HC+ luminometer. A Tvag TMA result over 50,000 RLU was considered positive. RESULTS Table 1. Sensitivity and Specificity of TMA vs Culture The sensitivity and specificity of the vaginal swab TMA test were 100% and 48.9% respectively. Given the very high false positive rate compared to the urine TMA test results a contamination problem was suspected. Relative light unit (RLU) readings from the TMA luminometer provide a crude estimate of the quantity of Tvag ribosome targets in each sample. Median RLUs was 3.5 X 106 for the culture positive/urine TMA positive cases compared to 3.3 X 106 for the culture negative/urine TMA positive cases. In contrast the median RLUs for the culture negative/vaginal swab TMA positive cases was only 757,000 compared to 4.0 X 106 for the culture positive/vaginal swab TMA positive cases. This result along with the low specificity of vaginal swab TMA compared to urine TMA suggested to us that the majority of vaginal swab positive results were false positive. Culture was positive in 87/400 (21.8%) of women. As shown in Table 1, the sensitivity and specificity of the urine TMA tests were 93.1% and 95.2% respectively. As can be seen in Table 2, of the six TMA urine false negative results, four were both wet preparation and culture positive. Of the 15 “false positive” urine TMA results, one was wet preparation positive and, therefore, probably represented a false negative culture. A repeat urine TMA test result was positive in this case. There were 14 wet preparation/culture negative cases that were urine TMA positive (Table 2). Of these 14 cases, 8 were negative on repeat testing. To determine the source of contamination all clinical and laboratory procedures were reviewed. The investigation revealed that a common container was used by clinical research personnel to temporarily hold vaginal swabs while they completed the pelvic examination (Figure 5). This procedure seemed reasonable as it appeared that only the shafts of the swabs directly touched the container walls. However, there was no other step in the specimen collection or handling protocols that could have accounted for the large number of vaginal swab false positives. TMA Positive/Culture Positive Urine Vaginal Swab Sensitivity 81/87 (93.1%) 87/87 (100%) Specificity 298/313 (95.2%) 152/311 (48.9%) Figure 1. Trichomonas vaginalis TMA Assay Procedure Table 2. Test Results by Wet Prep, Culture and Urine TMA 396 Total Cases* Wet Preparation Culture TMA Urine 51 Positive 4 Negative 1+ 30 7 2 14§ 287 Manual sample pipetting Addition of target capture reagent Washing with wash buffer using target capture system Incubation for TMA Addition of probe , selection and detection reagents Reading using luminometer Addition of oil, amplification and enzyme reagents REFERENCES *Gen-Probe’s Trichomonas vaginalis assay is in research. INTRODUCTION Trichomonas vaginalis (Tvag) is a common cause of sexually transmitted disease (STD), with an estimated 5 million new cases occurring annually in the U.S. From 10 to 50% of infections are asymptomatic. Diagnosis of Tvag infection is problematic. The commonly used wet mount, while rapid, has low sensitivity as does the Pap’s smear. Culture has greater sensitivity but takes up to five days. A rapid, amplified assay system is described here for the detection of Tvag from female vaginal swabs and matching urine specimens. An important goal of this study was to determine if female urine specimens would have adequate sensitivity to be used as screening samples for Tvag detection. CONCLUSIONS Figure 2. Target Capture Step *Wet preparation results missing in 4 cases. +A repeat TMA test using the remnant original specimen was positive in this case. §6/14 repeat TMA tests were positive. Figure 3. TMA Step The Tvag TMA assay method is easy to perform. The test could be automated or semi-automated, and the steps are identical to the GEN-PROBE® APTIMA® COMBO 2 Assay method currently used in many clinical laboratories. Overall, urine specimens tested by TMA appears to have promise for screening for trichomoniasis in women and could be a useful tool for population based studies of this infection where pelvic examinations are not practical. A prospective clinical trial utilizing an alternative rRNA region as a target for a confirmation assay is needed to better understand the true perfomance characteristics of the Tvag TMA assay for urine specimens. We experienced a significant contamination problem with vaginal swabs tested by TMA. The organism load in women with trichomoniasis often is very high. Furthermore, Tvag contains multiple copies of the rRNA gene. These two factors no doubt increase the risk of cross contamination of specimens during the collection process. Clinicians should be aware of the potential for contaminating specimens intended for nucleic acid amplification testing in the course of collecting female genital tract specimens for all organisms but especially for Tvag. Figure 5. Holding Cup for Vaginal Swabs. Same cup was used for multiple patients probably resulting in contamination. MATERIALS AND METHODS Vaginal swabs and matching urine specimens were collected from 400 women attending the New Orelans Delgado STD clinic. Ninety-five percent of the women were African American. The following tests were performed to detect Tvag at the LSU Health Sciences Center STD Pathogens Laboratory, using vaginal swabs specimens: Culture (In-PouchTM TV, BioMed Diagnostics, Inc., San Jose, CA) with microscopic examination on days 1, 3 and 5 post innoculation. Wet Mount The specimens were placed in Gen-Probe Incorporated swab and urine transport media tubes and stored at 2-8oC until testing. The TMA tests were performed at the LSU laboratory. Figure 4. HPA Step